Zuclopenthixol
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
- Zuclopenthixol
- Zuclopenthixol: From Schizophrenia to Retinal Dystrophy with or without Extraocular Anomalies
Zuclopenthixol: From Schizophrenia to Retinal Dystrophy with or without Extraocular Anomalies
One-Sentence Summary
Zuclopenthixol is a thioxanthene antipsychotic, originally used to treat schizophrenia. The TxGNN model predicts it may be effective for retinal dystrophy with or without extraocular anomalies, but no clinical trials and no publications currently support this prediction, so it rests on a computational score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Schizophrenia (from the knowledge graph; the Singapore licence record contains no indication text) |
| Predicted New Indication | Retinal dystrophy with or without extraocular anomalies |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for the original use is not available in the data compiled for this report. Based on known pharmacology, zuclopenthixol is a thioxanthene antipsychotic that mainly blocks dopamine D1/D2 receptors, with additional 5-HT2A and alpha1-adrenergic antagonism. Its efficacy in schizophrenia is established.
For retinal dystrophy, no mechanistic link has been established. Retinal dystrophies are typically monogenic disorders of photoreceptors or retinal structure, and they have no known connection to dopamine receptor blockade. The very high TxGNN score (0.99994) reflects an inference from the knowledge graph only. Neither trials nor publications back it up, so the score should be treated as a hypothesis-generating signal, not as evidence of benefit.
Other Predictions from the Model
Eight further indications were also predicted. All are at evidence level L5 with a recommendation of Hold:
| Rank | Predicted Indication | TxGNN Score | Mechanistic Assessment |
|---|---|---|---|
| 2 | Hydranencephaly | 99.99% | Structural brain malformation; receptor antagonism cannot reverse it. Poor fit for paediatric use. |
| 3 | Congenital disorder of glycosylation with defective fucosylation | 99.99% | Glycan biosynthesis disorder; no known effect of the drug on this pathway. |
| 4 | Charcot-Marie-Tooth disease, demyelinating, type 1G | 99.99% | Myelin protein defect; antipsychotic neurological side effects could complicate use. |
| 5 | Myopia, X-linked | 99.99% | Retinal dopamine influences eye growth, but the evidence favours dopamine agonism, whereas this drug is an antagonist. |
| 6 | Polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | 99.99% | Developmental cortical malformation; no plausible mechanism. |
| 7 | Syndromic myopia | 99.99% | Speculative dopamine link in the unfavourable direction. |
| 8 | Myopia 26, X-linked, female-limited | 99.99% | Genetic form (ARR3); no known relationship to the drug's pharmacology. |
| 9 | Atypical glycine encephalopathy | 99.99% | Glycine cleavage and mitochondrial defect; the drug does not act on these pathways. |
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN01365P | CLOPIXOL DEPOT INJECTION 200 mg/ml (H Lundbeck A/S) | Injection | Not stated in the licence record |
Safety Considerations
Please refer to the package insert for safety information.
Note that no drug interaction records were found, and no knowledge-graph contraindications were listed. This does not mean the drug is free of such risks. As a dopamine antagonist, antipsychotics of this class can cause extrapyramidal adverse effects, which is especially relevant for the neuropathy and paediatric-onset conditions among the predictions.
Conclusion and Next Steps
Decision: Hold
Rationale: The predictions rest solely on knowledge-graph scores, with no trials, no publications, and no plausible mechanism. For the myopia-related predictions, the known direction of dopamine effects is opposite to what an antagonist would be expected to do. The package insert safety data have also not yet been obtained.
To proceed, the following is needed:
- The package insert warnings and contraindications from the HSA (currently a blocking gap for safety screening)
- Detailed mechanism-of-action data from DrugBank
- A systematic literature and trial search for the predicted indications, particularly retinal dystrophy
- Preclinical or mechanistic evidence showing a rationale for dopamine antagonism in the predicted conditions
- An assessment of route compatibility (the only licensed form is a depot injection) and suitability for the target populations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.